Today: 22 January 2026
Subscribe
Browse Category

Pharmaceuticals News 26 November 2025 - 30 November 2025

AbbVie (ABBV) Stock Outlook Before the December 1, 2025 Open: Skyrizi’s Canada Win, Medicare Cuts and Fresh Analyst Targets

AbbVie (ABBV) Stock Outlook Before the December 1, 2025 Open: Skyrizi’s Canada Win, Medicare Cuts and Fresh Analyst Targets

AbbVie Inc. (NYSE: ABBV) heads into Monday’s December 1, 2025 open sitting near the middle of its recent trading range, with a lot of fresh information for investors to digest from November 28–30. As of the latest close on November 30, AbbVie shares are trading in the mid‑$220s — around $227 per share — after a strong year (roughly 30%+…
30 November 2025
····
Eli Lilly (LLY) Stock Outlook Before Market Open on December 1, 2025: Trillion‑Dollar Rally Pauses After Policy Shock

Eli Lilly (LLY) Stock Outlook Before Market Open on December 1, 2025: Trillion‑Dollar Rally Pauses After Policy Shock

Published: November 30, 2025 Eli Lilly and Company (NYSE: LLY) heads into Monday’s session after one of the most consequential months in its history: a brief stint above a $1 trillion market value, a huge November rally powered by obesity drugs, and a late‑month pullback as investors digest aggressive US drug‑pricing deals and sky‑high valuations. With US markets closed over…
30 November 2025
····
Merck (MRK) Stock on November 30, 2025: Price, Fresh Analyst Calls, Cidara Deal and Dividend Outlook

Merck (MRK) Stock on November 30, 2025: Price, Fresh Analyst Calls, Cidara Deal and Dividend Outlook

Merck & Co., Inc. (NYSE: MRK) heads into the last month of 2025 with its share price near the top of its 52‑week range, a richer pipeline, and a wave of new research coverage and corporate news that investors are digesting in real time. As of the last trading session on Friday, November 28, 2025, Merck stock closed at $104.83,…
30 November 2025
···
Eli Lilly Stock on November 30, 2025: Trillion‑Dollar Pharma, GLP‑1 Boom and Valuation Jitters Around LLY

Eli Lilly Stock on November 30, 2025: Trillion‑Dollar Pharma, GLP‑1 Boom and Valuation Jitters Around LLY

Eli Lilly and Company (NYSE: LLY) has just wrapped up one of the most dramatic months in its history. The drugmaker’s shares have surged in November, pushing the company past a $1 trillion market value and cementing its role as the stock market’s flagship obesity‑drug play. At the same time, fresh commentary this weekend is increasingly focused on one question:…
30 November 2025
····
AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

Published: November 29, 2025 AbbVie Inc. (NYSE: ABBV) heads into the final stretch of 2025 trading just below its record highs, after a powerful rally driven by immunology blockbuster drugs Skyrizi and Rinvoq. The stock closed at $227.70 on Friday, November 28, up 0.02% on the day and sitting within a 52‑week range of roughly $164 to $245. StockAnalysis Year…
29 November 2025
····
Eli Lilly (LLY) Stock Today: Trillion‑Dollar Weight‑Loss Giant Pulls Back After November Surge

Eli Lilly (LLY) Stock Today: Trillion‑Dollar Weight‑Loss Giant Pulls Back After November Surge

By [Author Name] – November 29, 2025 Eli Lilly and Company’s stock has cooled after an explosive November rally that briefly turned the 149‑year‑old drugmaker into the world’s first trillion‑dollar pharmaceutical company. Reuters On Friday, November 28, Eli Lilly (NYSE: LLY) closed at $1,075.47, down about 2.6% on the day, dragging the S&P 500 healthcare sector into the red even…
29 November 2025
···
Johnson & Johnson Stock (JNJ) Near Record Highs: Halda Deal, Spin‑Off Plans and Talc Risks on November 28, 2025

Johnson & Johnson Stock (JNJ) Near Record Highs: Halda Deal, Spin‑Off Plans and Talc Risks on November 28, 2025

Updated: November 28, 2025 Johnson & Johnson (JNJ) is closing out 2025 as one of the standout “defensive” winners in the U.S. market. The stock is trading just below a fresh 52‑week high around $205–$208 per share, giving the healthcare giant a market capitalization of roughly $500 billion. FinancialContent Over the last three months, JNJ shares have climbed about 17–18%,…
28 November 2025
···
Pfizer Stock Today (PFE), November 28, 2025: Guggenheim Upgrade, Norges Bank Stake and a 6.7% Dividend Yield

Pfizer Stock Today (PFE), November 28, 2025: Guggenheim Upgrade, Norges Bank Stake and a 6.7% Dividend Yield

Published: November 28, 2025 – mid‑session U.S. trading Pfizer stock price today: PFE edges higher in midday trade Pfizer stock (NYSE: PFE) is trading around $25.8 per share in late morning trading on Friday, November 28, 2025, up roughly 0.3% from yesterday’s close near $25.72. MarketBeat That keeps PFE: Performance-wise, MarketBeat data show Pfizer is down about 3% year‑to‑date, roughly…
28 November 2025
····
GSK plc Stock Today, 28 November 2025: Buybacks, ‘Hold’ Ratings and Pipeline Momentum Keep Shares Near Highs

GSK plc Stock Today, 28 November 2025: Buybacks, ‘Hold’ Ratings and Pipeline Momentum Keep Shares Near Highs

GSK plc (LON:GSK; NYSE:GSK) is drifting quietly higher on Friday, 28 November 2025, with investors digesting a fresh “Hold” consensus from Wall Street, another round of share buybacks and a still‑busy drug pipeline that has pushed the stock close to 12‑month highs. In London, GSK’s shares are trading around 1,806p, up roughly 0.2% on the day, within a narrow intraday…
28 November 2025
····
Novo Nordisk (NVO) Stock Rebounds as Wegovy Upgrade and Medicare Deal Ease Pricing Fears – 26 November 2025

Novo Nordisk (NVO) Stock Rebounds as Wegovy Upgrade and Medicare Deal Ease Pricing Fears – 26 November 2025

Novo Nordisk A/S stock is staging a sharp rebound today, 26 November 2025, as investors digest a trio of major developments: an FDA filing for a higher-dose version of its blockbuster obesity drug Wegovy, clarity on steep—but largely expected—Medicare price cuts for Ozempic and Wegovy, and fresh enthusiasm around its next‑generation obesity candidate amycretin. As of 20:48 UTC on 26…
26 November 2025
····
Pfizer Stock Today, November 26, 2025: Obesity Bet, Cancer Breakthrough and Legal Risks Shape PFE’s Outlook

Pfizer Stock Today, November 26, 2025: Obesity Bet, Cancer Breakthrough and Legal Risks Shape PFE’s Outlook

Pfizer Inc. (NYSE: PFE) spent Wednesday trading slightly lower despite a stream of fresh headlines that cut both ways for sentiment. The stock hovered around $25.7, giving back a fraction of Tuesday’s nearly 2% gain, as investors weighed upbeat news on obesity drugs, cancer treatment and vaccines against ongoing legal and regulatory risks. MarketScreener Below is a structured look at…
26 November 2025
···
Merck (MRK) Stock Today – November 26, 2025: Keytruda Wins, Analyst Upgrades and Big Money Buying Keep Shares Near Record Highs

Merck (MRK) Stock Today – November 26, 2025: Keytruda Wins, Analyst Upgrades and Big Money Buying Keep Shares Near Record Highs

Merck & Co., Inc. (NYSE: MRK) spent Wednesday trading just below fresh 52‑week highs, as Wall Street continues to digest a powerful mix of positive drug news, upbeat earnings, and a wave of analyst upgrades and institutional buying. Merck stock price today: holding near record territory Merck shares closed today around $105.3 per share, slipping only a few tenths of…
26 November 2025
····
1 … 32 33 34 35 36 … 46

Stock Market Today

  • BitGo CEO Mike Belshe on IPO Timing and Crypto Custody Strategy
    January 22, 2026, 2:18 PM EST. BitGo CEO Mike Belshe discussed the timing of the company's IPO, emphasizing a long-term commitment to the digital asset space despite current crypto price stagnation. The IPO process began last fall but was delayed to January due to government holidays. Belshe highlighted significant market growth, noting BitGo's total addressable market doubled last year and has doubled again recently amid regulatory changes. He clarified that BitGo is not just a custodian but an infrastructure provider focused on institutional clients, offering high compliance and security standards. The company distinguishes itself by providing fiduciary-level protection to all clients, retail and institutional, and generates revenue from ancillary services such as trading, staking, and borrowing.
Go toTop